Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

107 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-01-31

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a retrospective analysis to explore the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the efficacy and safety of chemotherapy, and overall survival rate in lymphoma patients with hepatitis B virus infection.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP

NCT01210287

Lymphoma

UNKNOWN PHASE2/PHASE3

Incidence of Hepatitis B Reactivation in Non-Hodgkin's Lymphoma Patients

NCT00931229

Non-Hodgkin's Lymphoma

UNKNOWN NA

The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide

NCT03804372

Large-B-cell Diffuse Lymphoma Chronic Lymphoid Leukemia

TERMINATED PHASE2

Factors Influencing Hepatitis B Virus Reactivation in Lymphoma Patients Treated With Rituximab

NCT01311232

Patients With Diffuse Large B-cell Lymphoma or Follicular Lymphoma Patients Treated With Rituximab-CHOP or Rituximab-CVP

COMPLETED

A Comparative Study for Non-Hodgkin's Lymphoma in Hepatitis B Virus Carriers

NCT00262210

Non-Hodgkin's Lymphoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

All eligible patients received prophylactic antiviral therapy during and within 6 months after chemotherapy in previous sudy. We did not assign specific interventions to the subjects in this study. The primary endpoint of this study is the incidence of hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy. The secondary endpoints include the incidence of hepatitis flare related to hepatitis B virus reactivation after withdrawal of prophylactic antiviral therapy, the tumor response rate, and overall survival rate.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis Hepatitis B Lymphoma Hematologic Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group with HBV reactivation

group with hepatitis B virus reactivation

No interventions assigned to this group

group without HBV reactivation

group without hepatitis B virus reactivation

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* treatment-naive patients with lymphoma
* patients with a history of previous exposure to hepatitis B virus (HBV): HBsAg or hepatitis B core antibody (anti-HBc) positive